Jakafi is the first and only FDA-approved treatment across the 4 following indications1
PV
Polycythemia Vera
For treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea
MF
Myelofibrosis
For treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF in adults
aGVHD
Acute Graft-Versus-Host Disease
For treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older
cGVHD
Chronic Graft-Versus-Host Disease
For treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
- Recommend ruxolitinib (Jakafi) as a preferred treatment option for patients with high-risk PV who have had an inadequate response or loss of response to cytoreductive therapy2
- Recommend ruxolitinib (Jakafi) as a Category 1* initial treatment option for patients with higher-risk MF† and platelets ≥50 x 109/L and a Category 2A‡ treatment option for patients with symptomatic lower-risk MF2§
- Recommend ruxolitinib (Jakafi) as the ONLY Category 1 treatment option for steroid-refractory acute GVHD3*||
- Recommend ruxolitinib (Jakafi) as the ONLY Category 1 treatment option for steroid-refractory chronic GVHD3*||
- *Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.2,3
- †In patients who are not transplant candidates.2
- ‡Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.2
- §Lower-risk MF is defined as low or intermediate-1 risk based on DIPSS, DIPSS-Plus, and MYSEC-PM; low or intermediate risk based on MIPSS-70 (threshold of ≤3 prognostic variable points); and very low, low, or intermediate risk based on MIPSS-70+ Version 2.0 (threshold of ≤3 prognostic variable points).2
- ||The NCCN does not recommmend one systemic agent as preferred over another in steroid-refractory GVHD.3
DIPSS=Dynamic International Prognostic Scoring System; MIPSS=Mutation-enhanced International Prognostic Score System; MYSEC-PM=Myelofibrosis Secondary to PV; ET-Prognostic Model; NCCN=National Comprehensive Cancer Network®.
References: 1. Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 5, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation V.3.2022. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 30, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.